Physician profile
Allyson Smith
NPI 1710668553
$2,201.07
in general payments reported to CMS, 2019-2025
22 companies · $587 in 2025
The $587 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $467 · 2024: $1,148 · 2025: $587.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,201.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,201.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $275.51 | 2023-2025 | Jardiance |
| Amgen INC. | $245.35 | 2024 | Repatha |
| Pfizer INC. | $242.19 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $202.99 | 2023-2025 | |
| E.R. Squibb & Sons, L.L.C. | $176.60 | 2023-2025 | Camzyos |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $152.41 | 2023-2025 | Lifevest |
| Astrazeneca Pharmaceuticals Lp | $135.82 | 2023-2025 | Farxiga |
| Abiomed | $130.12 | 2025 | |
| Actelion Pharmaceuticals US, INC. | $124.56 | 2024 | Opsumit, Uptravi |
| Novo Nordisk INC | $112.47 | 2024 | Wegovy |
| Zoll Circulation INC | $103.00 | 2023 | Downstream Cartridge, Catheter, Therox Ds2 Console |
| Alnylam Pharmaceuticals INC. | $58.60 | 2024-2025 | Amvuttra |
| Daiichi Sankyo INC. | $51.59 | 2023 | Injectafer |
| Merck Sharp & Dohme LLC | $37.79 | 2024-2025 | Verquvo |
| Cvrx, INC. | $25.26 | 2025 | Barostim Neo System |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Zoll Respicardia, INC. | $24.57 | 2024 | Remede System |
| Corcept Therapeutics | $20.16 | 2023 | Korlym |
| Lexicon Pharmaceuticals, INC. | $18.73 | 2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $16.71 | 2023 | Arcalyst |
| Lilly USA, LLC | $16.28 | 2025 | Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $15.92 | 2024 | |
| Angiodynamics, INC. | $14.44 | 2024 | Auryon Laser System 100-120 Vac |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Allyson Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.